We have received confirmation from Mylan who distribute EpiPen® in the UK that additional stock of EpiPen® Senior Adrenaline Auto-Injector is available and measures remain in place to manage stock distribution. A statement from Mylan is below.
As some of the additional stock available will have an expiry date of October 2018, we advise you to check the expiry date on your Adrenaline Auto-Injectors when you receive them and not to dispose of any ‘expired’ AAI devices before you have obtained a new device. The expiry date will be printed on the casing and the adrenaline solution in your device should be clear and colourless. If the liquid in your device is not cloudy or discoloured, the AAI device can still be used in an emergency.
If you are worried about your prescription, we advise you to visit your GP and discuss this directly with them. Your GP can prescribe an alternative medication if required. The AAI devices prescribed in the UK at present are Emerade®, EpiPen® and Jext®.
If you are prescribed an alternative AAI device, ensure that you know how to use it. The place where adrenaline is administered is the same for all three injectors (the muscle in the front quarter of the outer thigh) but the method of administration for each AAI varies slightly. Training should be given to all those who might be required to administer your adrenaline in an emergency, such as family members and friends. Do continue to always carry your AAIs with you and follow your usual risk management techniques to avoid your allergen and reduce the likelihood that you will experience a severe allergic reaction and need to use your adrenaline.
The pharmaceutical companies who distribute AAIs have their own customer care departments and formal complaints procedures. If you have any concerns we encourage feedback to be given directly to the organisations responsible. Please speak to Mylan customer services in the first instance on +44 (0)1707 853 100.
You can also contact our helpline and information team at [email protected] or call 01252 542 029 for support between Monday-Friday, 9am-5pm.
Availability of EpiPen® 0.3mg Adrenaline Auto-Injector
Due to manufacturing delays from our contract manufacturer, Meridian Medical Technologies, a Pfizer company, there are intermittent supply constraints on EpiPen® 0.3mg Adrenaline Auto-Injector in the UK.
Latest Supply Status
Distribution of EpiPen® 0.3mg Adrenaline Auto-Injector is being carefully monitored, in coordination with our UK distribution partner, Alliance Healthcare, to help manage product availability on an ongoing basis until a steady supply resumes. In late April, we initiated a stock management process for EpiPen® 0.3mg Adrenaline Auto-Injector in which pharmacies are allocated product on a prescription-only basis and can place orders for up to a maximum of two EpiPen® 0.3mg Auto-Injectors per prescription. This process is still in place.
To further support the continuity of supply and immediate market demand, we have secured a limited volume of EpiPen® 0.3mg Adrenaline Auto-Injectors with an expiry date of October 2018. This supply is not subject to the current prescription validation process, as outlined above, and will be offered to pharmacists to order and have in stock. The product meets all required quality standards.
With patient access as our priority, we will continue to proactively and diligently update pharmacies, healthcare professionals and patient advocacy groups across the country regarding any changes in stock availability.
There are currently sufficient supplies of EpiPen Jr® 0.15mg Adrenaline Auto-Injectors in the UK.
Ongoing Supply Management
Mylan is working closely with Pfizer to manage supply carefully to avoid long-term supply shortages. Pfizer anticipates that production rates will increase over the coming months; however, at this time, cannot commit to a specific time for when the supply constraint will be fully resolved. We are confident in the safety and efficacy of the EpiPen® products being produced at Pfizer’s site and are working closely with them to alleviate the situation and achieve a steady state of supply as expeditiously as possible.
Information for Patients
Mylan is unable to make any specific treatment recommendation to individual patients. Patients should speak to their healthcare provider for appropriate actions to be taken.
If you require additional information or have any questions, please contact +44(0) 1707 853 100.